1 |
Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605-12.
DOI
ScienceOn
|
2 |
Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35:7S-14S.
DOI
ScienceOn
|
3 |
Letavernier E, Pe'raldi MN, Pariente A, Morelon E, Legendre C. Proteinuria following a switch from calcineurin inhibitors to sirolimus Transplantation. 2005;80:1198-203.
DOI
ScienceOn
|
4 |
Rangan GK. Sirolimus-associated proteinuria and renal dysfunction. Drug Saf 2006; 29:1153-61.
DOI
ScienceOn
|
5 |
Diekmann F, Gutierrez-Dalmau A, Lopez S, Cofan F, Esforzado N, Ricart MJ, et al. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Nephrol Dial Transplant 2007;22:2316-21.
DOI
ScienceOn
|
6 |
Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14:931-8.
DOI
ScienceOn
|
7 |
Stallone G, Infante B, Schena A, Battaglia M, Ditonno P, Loverre A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005;16:3755-62.
DOI
ScienceOn
|
8 |
Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005;20:2517-23.
DOI
ScienceOn
|
9 |
Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP; Sirolimus Renal Function Study Group. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002;74:1560-7.
DOI
ScienceOn
|
10 |
Boratynska M, Banasik M, Watorek E, Falkiewicz K, Patrzałek D, Szyber P, et al. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc 2006;38:101-4.
DOI
ScienceOn
|
11 |
Franco AF, Martini D, Abensur H, Noronha IL. Proteinuria in transplant patients associated with sirolimus. Transplant Proc 2007; 39:449-52.
DOI
ScienceOn
|
12 |
Izzedine H, Brocheriou I, Frances C. Posttransplantation proteinuria and sirolimus. N Engl J Med 2005;353:2088-9.
|
13 |
Letavernier E, Legendre C. mToR inhibitors- induced proteinuria: mechanisms, significance, and management. Transplant Rev(Orlando). 2008;22:125-30.
DOI
ScienceOn
|
14 |
Han GD, Suzuki K, Koike H, Suzuki K, Yoneyama H, Narumi S, et al. IFN-inducible protein-10 plays a pivotal role in maintaining slit-diaphragm function by regulating podocyte cell-cycle balance. J Am Soc Nephrol 2006;17:442-53.
DOI
ScienceOn
|
15 |
Sennesael JJ, Bosmans JL, Bogers JP, Verbeelen Verbeelen D, Verpooten GA. Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation 2005; 80:1578-85.
DOI
ScienceOn
|
16 |
Kwoh C, Shannon MB, Miner JH, Shaw A. Pathogenesis of nonimmune glomerulopathies. Annu Rev Pathol 2006;1:349-74.
DOI
ScienceOn
|
17 |
Kawachi H, Miyauchi N, Suzuki K, Han GD, Orikasa M, Shimizu F. Role of podocyte slit diaphragm as a filtration barrier. Nephrology (Carlton) 2006;11:274-81.
DOI
ScienceOn
|
18 |
Kerjaschki D. Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 2001;108: 1583-7.
DOI
|
19 |
Vollenbroker B, George B, Wolfgart M, Saleem MA, Pavenstadt H, Weide T. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 2009;296: F418-26.
DOI
|
20 |
Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000;356:194-202.
|
21 |
Kokui K, Yoshikawa N, Nakamura H, Itoh H. Cyclosporin reduces proteinuria in rats with aminonucleoside nephrosis. J Pathol 1992; 166:297-301.
DOI
|
22 |
Meyrier A. Antiproteinuric and immunological effects of cyclosporin A in the treatment of glomerular diseases. Nephrol Dial Transplant 1992;7:S80-4.
|
23 |
Nacar A, Kiyici H, Ogus E, Zagyapan R, Demirhan B, Ozdemir H, et al. Ultrastructural examination of glomerular and tubular changes in renal allografts with cyclosporine toxicity. Ren Fail 2006;28:543-7.
DOI
ScienceOn
|
24 |
DiJoseph JF, Sharma RN, Chang JY. The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation 1992; 53:507-13.
DOI
ScienceOn
|
25 |
Liew A, Chiang GS, Vathsala A. Factors associated with proteinuria in renal transplant recipients treated with sirolimus. TransplInt 2009;22:313-22.
|
26 |
Ruiz JC, Campistol JM, Sanchez-Fructuoso A, Mota A, Grinyo JM, Paul J, et al. Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria. Transplant Proc 2007;39:2151-2.
DOI
ScienceOn
|
27 |
Abbate M, Zoja C, Corna D, Capitanio M, Bertani T, Remuzzi G. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 1998;9:1213-24.
|
28 |
Straathof-Galema L, Wetzels JF, Dijkman HB, Steenbergen EJ, Hilbrands LB. Sirolimus- associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 2006;6:429- 33.
DOI
ScienceOn
|
29 |
Mreich E, Coombes JD, Rangan GK. Sirolimus does not reduce receptor-mediated endocytosis of albumin in proximal tubule cells. Transplantation 2007;83:105-7.
DOI
ScienceOn
|
30 |
Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996;50: 1089-100.
DOI
ScienceOn
|
31 |
Saurina A, Campistol JM, Piera C, Diekmann F, Campos B, Campos N, et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 2006;21:488-93.
DOI
ScienceOn
|
32 |
van den Akker JM, Wetzels JF, Hoitsma AJ. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 2006;70:1355-7.
DOI
ScienceOn
|
33 |
Letavernier E, Bruneval P, Mandet C, Van Huyen JP, Peraldi MN, Helal I, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007;2:326-33.
DOI
ScienceOn
|
34 |
Letavernier E, Bruneval P, Vandermeersch S, Perez J, Mandet C, Belair MF, et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009;24:630-8.
|
35 |
Patari-Sampo A, Ihalmo P, Holthofer H. Molecular basis of the glomerular filtration: nephrin and the emerging protein complex at the podocyte slit diaphragm. Ann Med 2006;38:483-92.
DOI
ScienceOn
|
36 |
Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4:378-83.
DOI
ScienceOn
|
37 |
Weir MR, Blahut S, Drachenburg C, Young C, Papademitriou J, Klassen DK, et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004;24:379-86.
DOI
ScienceOn
|
38 |
Andrassy J, Graeb C, Rentsch M, Jauch KW, Guba M. mTOR inhibition and its effect on cancer in transplantation. Transplantation 2005;80:S171-4.
DOI
ScienceOn
|
39 |
Morath C, Arns W, Schwenger V, Mehrabi A, Fonouni H, Schmidt J, et al. Sirolimus in renal transplantation. Nephrol Dial Transplant 2007;22:viii61-viii65.
DOI
|
40 |
Lee VW, Chapman JR. Sirolimus: its role in nephrology. Nephrology (Carlton) 2005;10: 606-14.
DOI
ScienceOn
|
41 |
Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996;98:2277-83.
DOI
ScienceOn
|
42 |
He Z, Chen L, Qiu J, Li J, Zhao D, Chen G, et al. Conversion from cyclosporin A to sirolimus retards the progression of chronic allograft nephropathy in the long term in a rat kidney transplantation model. J Int Med Res 2009;37:1396-410.
DOI
ScienceOn
|